P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As 2 O 3 ), but are not the main mechanism of As 2 O 3 -resistance in acute promyelocytic leukemia cells Leukemia (2003) 17, 648-650. doi:10.1038/sj.leu.2402851 TO THE EDITOR Trioxide (As 2 O 3 ) represents a great advance in the management of patients with relapsed or refractory acute promyelocytic leukemia (APL). However, As 2 O 3 resistance has been reported at diagnosis or as arising during treatment with As 2 O 3 in some cases. Several investigators have studied the mechanisms of As 2 O 3 -resistance, and reported an alteration of cellular glutathione levels and the involvement of drug efflux pumps such as MDR-associated protein (MRP) and P-glycoprotein (P-gp). 1, 2 In some reports, drug-resistance modifiers restored the intracellular accumulation of As 2 O 3 .
2-4 Therefore, As 2 O 3 might also be affected by these transportation systems, and intracellular accumulation of As 2 O 3 may be decreased in As 2 O 3 -resistant APL cells. In this study, we aimed to clarify the relation between these drug-resistance mechanisms and As 2 O 3 -resistance in APL cells. We also assessed the intracellular accumulation of As 2 O 3 in APL cell lines and blast cells from patients with APL cells, because this has not been analyzed previously from the viewpoint of As 2 O 3 -resistance in APL.
Cells used in this study were an APL cell line (NB4) in which P-gp was undetectable, NB4 transfected with MDR-1 cDNA (NB4/MDR), As 2 O 3 -resistant NB4 (NB4/As) and blast cells from 14 patients with clinically ATRA-resistant APL including three patients with clinically As 2 O 3 -resistant APL. NB4/MDR and NB4/As cells were obtained as described in our previous reports. 8 The degree of dissociation between the fluorescence intensity (FI) of cells that reacted with MRK16 or MRPm6 MoAb and the FI of cells stained with respective control MoAb was analyzed by the channel-bychannel subtraction method, and the degree of dissociation was defined as the amount (%) of P-gp or MRP1.
6 P-gp function was determined by rhodamine-123 (Rh123) accumulation and its inhibition by PSC833 (Novartis Pharma, Basel, Switzerland) or MS209 (Mitsui Pragmatics, Tokyo, Japan).
6 MRP1 function was determined by calcein acetoxymethyl ester (calcein-AM) (Dojin Chem., Kumamoto, Japan) efflux and its inhibition by probenecid. 6 The accumulation (%) of Rh123 and the efflux (%) of calcein-AM were determined as reported previously. 6 The amount of mdr-1 and mrp-1 mRNA were determined by realtime PCR analysis. The primer set to amplify mdr-1 and mrp-1 mRNA was designed according to Genbank M14758 and Genbank NM004996, respectively. The primer set for amplification of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA, as an internal control, was designed according to Genbank M33197. Each PCR reaction was carried out over 50 cycles using a real-time PCR system (ABI PRISM 7700 Sequence Detection System s , PE Applied Biosystems). Intracellular As 2 O 3 was determined by the atomic extinction flame emission method in triplicate after incubating cells with 1 mM As 2 O 3 at 371C for 6 h. Cellular As 2 O 3 concentration was calculated from the As content.
P-gp was not detectable in NB4 cells by the immunofluorescence assay, but was present in NB4/As cells (Table 1 ). In the Pgp functional analysis, NB4/As cells accumulated less Rh123 than NB4 cells. However, both the amount and function of P-gp in NB4/As cells were less than that in NB4/MDR cells. The amount and function of MRP1 in NB4/As cells were greater than in NB4 cells (Table 1) . NB4/As cells expressed more mdr-1 and mrp-1 than NB4 cells. This result was well correlated with that from the P-gp analysis. Despite these differences in P-gp expression, there were no significant differences between NB4, NB4/MDR and NB4/As cells in the intracellular accumulation of As 2 O 3 (6.270.4, 6.270.5 and 6.270.4, respectively). MDR modifiers (PSC833 or MS209) and an MRP modifier (probenecid) did not increase intracellular As 2 O 3 accumulation in NB4/MDR or NB4/As cells. At 1 mM As 2 O 3 (similar to the blood arsenic levels achieved by As 2 O 3 treatment in APL patients), no significant morphological differences were observed between NB4 and NB4/MDR cells.
Similar results were obtained using blast cells from 14 APL patients. The clinical outcome of As 2 O 3 treatment was not related to the amount or the function of P-gp (P ¼ 0.85 and 0.93, respectively), or to the intracellular accumulation of As 2 O 3 (P ¼ 0.53). Neither was it related to the amount or function of MRP1 (P ¼ 0.39 and 0.20, respectively). Five APL patients, whose leukemia cells expressed considerable amounts of P-gp and/or MRP1, entered cytogenetic complete remission (CR). On the other hand, a patient whose leukemia cells expressed neither P-gp nor MRP1 failed to respond to As 2 O 3 treatment. In all three As 2 O 3 -resistant cases, the amount and function of P-gp in leukemia cells increased after As 2 O 3 treatment compared to the pretreatment values. In five cases that relapsed again after arsenic acid-induced remission, a comparison could be made with the situation before the previous As 2 O 3 treatment. In four of these cases, the amount and function of P-gp also increased after As 2 O 3 treatment.
Treatment of APL not only with chemotherapeutic agents but also with ATRA and As 2 O 3 has recently been introduced. Therefore, we must recognize the possibility of cross-resistance among these agents. Although it is considered that multidrug-, ATRA-and As 2 O 3 -resistance are clinically unrelated to each other, this idea has not been confirmed. Perkins et al 7 also reported that As 2 O 3 induced apoptosis in MDR-expressing human leukemia cells. Lehmann et al 8 reported that As 2 O 3 induced apoptosis and cytotoxic effects in non-M3 AML. In the present study, we have demonstrated that As 2 O 3 resistance was independent of MDR in APL, and that As 2 O 3 was also effective in cells that expressed considerable amounts of P-gp. Although As 2 O 3 could induce the expression of P-gp, it did not influence intracellular As 2 O 3 concentrations and had little effect on As 2 O 3 -resistance at the concentrations of the drug achieved clinically. From the viewpoint of P-gp induction, the use of As 2 O 3 may reduce the effect of subsequent chemotherapy in APL because of the possible induction of P-gp. NB4/MDR cells contain markedly greater amounts of P-gp than would be present in blast cells in APL patients. In addition, the amount of P-gp in blast cells from APL is significantly less than in other types of AML. Therefore, P-gp may not represent a major clinical problem at the concentrations of As 2 O 3 achievable in patients. However, excessive dose reduction may result not only in As 2 O 3 -resistance but also in resistance to chemotherapeutic agents. With regard to other mechanisms of As 2 O 3 -resistance, cellular glutathione levels and MRP were reportedly related to arsenic resistance. [2] [3] [4] These two factors seem to be related to each other. In our previous work, NB4/As cells were found to possess higher levels of intracellular glutathione than NB4 cells. 1 In the present study, we could show by three different methods that NB4/As cells expressed more MRP1 than NB4 cells. However, probenecid failed to alter the intracellular concentration of As 2 O 3 and overcome As 2 O 3 -resistance in NB4/ As cells. Perkins et al 7 failed to detect increased resistance to As 2 O 3 in MRP-overexpressing HL60 cells. In their study using drug-resistance modifiers, acquired As 2 O 3 -resistance was abolished when cells were exposed to an inhibitor of GST-II (a glutathione synthesis inhibitor), MK571 (a specific inhibitor of MRP1) or PSC833 (a specific inhibitor of P-gp). Thus, several different mechanisms may contribute to As 2 O 3 -resistance concurrently. In hepatocytes and other tumor cells, overexpression of the membrane transporters reportedly decreased intracellular accumulation of As 2 O 3 and could confer As 2 O 3 -resistance. 3 In APL cells, intracellular concentrations of As 2 O 3 have not yet been analyzed systematically in association with Infection Diseases, Nagoya University, Nagoya, Japan;
